U.S. Pharmacopeia ( usp ), the independent, scientific nonprofit organization focused on building trust in the supply of safe, quality medicines, will host a three-part series of conversations with key stakeholders dedicated to strengthening the medicines supply chain.
The series will bring together USP Convention Members representing patient, provider, scientific, regulator, and industry perspectives to examine key points along the pharmaceutical supply chain. The depth and breadth of the USP Convention Membership provides diverse knowledge, insights, and expertise, ensuring a robust dialogue.
The first conversation in the series, “Reducing Barriers to Adoption of Advanced Manufacturing Technology,” will feature Convention Member representatives and stakeholders from the Association for Accessible Medicines, the National Institute of Standards and Technology and Research!America, as well as USP leaders. Taking place on February 25, 2022, the event will focus on the role of advanced manufacturing technology in maintaining the quality of medicines throughout the supply chain and approaches for reducing barriers to its adoption.
The remaining two conversations on preparing the medicines supply chain for resilience ahead of future disruptions and successes and strategies for multinational cooperation will take place in March and May, respectively.
“In recent months, supply chain challenges have been the subject of much media coverage and political dialogue,” said Anthony Lakavage, J.D., senior vice president, Global External Affairs and Secretary of the USP Convention. “While many of the challenges aren’t new, COVID-19 has added urgency and an opportunity to strengthen the resilience of the pharmaceutical supply chain. The supply chain for medicines is complex and spans the globe – no one government, organization, or company has all the solutions or capacity to strengthen the supply chain alone; perspectives, input, expertise, and resources from many sectors are needed. Convening the USP Convention membership and its 450 members from across the health and science community offers a diverse set of perspectives to help inform investments and policy reforms to enhance resiliency into the future.”
The series will bring together USP Convention Members representing patient, provider, scientific, regulator, and industry perspectives to examine key points along the pharmaceutical supply chain. The depth and breadth of the USP Convention Membership provides diverse knowledge, insights, and expertise, ensuring a robust dialogue.
The first conversation in the series, “Reducing Barriers to Adoption of Advanced Manufacturing Technology,” will feature Convention Member representatives and stakeholders from the Association for Accessible Medicines, the National Institute of Standards and Technology and Research!America, as well as USP leaders. Taking place on February 25, 2022, the event will focus on the role of advanced manufacturing technology in maintaining the quality of medicines throughout the supply chain and approaches for reducing barriers to its adoption.
The remaining two conversations on preparing the medicines supply chain for resilience ahead of future disruptions and successes and strategies for multinational cooperation will take place in March and May, respectively.
“In recent months, supply chain challenges have been the subject of much media coverage and political dialogue,” said Anthony Lakavage, J.D., senior vice president, Global External Affairs and Secretary of the USP Convention. “While many of the challenges aren’t new, COVID-19 has added urgency and an opportunity to strengthen the resilience of the pharmaceutical supply chain. The supply chain for medicines is complex and spans the globe – no one government, organization, or company has all the solutions or capacity to strengthen the supply chain alone; perspectives, input, expertise, and resources from many sectors are needed. Convening the USP Convention membership and its 450 members from across the health and science community offers a diverse set of perspectives to help inform investments and policy reforms to enhance resiliency into the future.”
